Alkermes
high unmet needs remain for treatment of ovarian cancer ovarian cancer burden limited treatment options second most common gynecological cancer prevalence cases in leading cause of gynecologic cancer related deaths in the year survival rate for stage ovarian cancer of median overall survival mos for platinum resistant ovarian cancer is less than months standard of care median progression free survival months standard of care surgery platinum based chemotherapy followed by and or inhibitor as maintenance many become platinum resistant refractory and progress months after completion of platinum based chemotherapy few treatment options post platinum chemotherapy in one study of non platinum chemotherapy objective response rate was and median progression free survival was months anti have been shown to be ineffective for treatment of ovarian cancer efficacy in ovarian cancer is for high expression maintenance expression | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
71 of 144
Related slides by other companies
Immix Biopharma
Investor Presentation
October 2023
glut targeted for cancer | Immix Biopharma
Nuvalent
Investor Presentation
January 2024
patient population heavily solid tumors phase characteristic age median range female tumor type pancreatic adenocarcinoma non smoker history of metastases measurable lesions data as of for patients treated by all data shown as unless otherwise ire eon includes patients with untreated lesions categories are not mutually exclusive source a treatment history prior lines of anticancer treatment median range prior treatments without chemotherapy and chemotherapy without chemotherapy and chemotherapy received other a | Nuvalent
Immatics
Investor Presentation
November 2023
gen melanoma as first indication for pivotal development cohort a | Immatics
Nuvalent
Investor Presentation
February 2024
patient population heavily solid tumors phase characteristic age median range female tumor type pancreatic adenocarcinoma non smoker history of metastases measurable lesions punted data as of for patients treated by all data shown as unless otherwise specified central nervous system eastern oncology group performance status non lung cancer response evaluation criteria in version tyrosine kinase includes patients with untreated lesions categories are not mutually exclusive source a treatment prior lines of anticancer treatment median range prior treatments without chemotherapy and chemotherapy without chemotherapy and chemotherapy received other cee | Nuvalent
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io